<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33296">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01692119</url>
  </required_header>
  <id_info>
    <org_study_id>PHARM-CHF</org_study_id>
    <nct_id>NCT01692119</nct_id>
  </id_info>
  <brief_title>Pharmacy-based Interdisciplinary Program for Patients With Chronic Heart Failure</brief_title>
  <acronym>PHARM-CHF</acronym>
  <official_title>Pharmacy-based Interdisciplinary Program for Patients With Chronic Heart Failure (PHARM-CHF): A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal Union of German Associations of Pharmacists</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Saarland University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Federal Union of German Associations of Pharmacists</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate, whether a continuous interdisciplinary intervention
      leads to a reduction of hospitalizations and mortality in elderly patients with chronic
      heart failure. The intervention, consisting of regular contacts with the local pharmacy and
      weekly dosing aids, aims to improve medication adherence and management.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>All-cause mortality or unplanned cardiovascular hospitalizations</measure>
    <time_frame>Participants will be followed for an expected average of 21 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>composite, recurrent event, number</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2060</enrollment>
  <condition>Chronic Heart Failure</condition>
  <arm_group>
    <arm_group_label>regular, pharmacy-based intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>providing medication in weekly dosing aids and regular contacts with the local pharmacy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>usual care</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Regular, pharmacy based intervention</intervention_name>
    <description>Regular, pharmacy-based intervention conducted in cooperation with the treating physician:
Medication review at baseline: recording of all medicines currently taken (prescribed medication and self-medication), check for drug-related problems, consolidation of a medication plan.
Regularly (weekly): dose-dispensing of the medication (weekly dosing aid), discussion and counseling regarding medication, adherence, potential side effects, and signs and symptoms of cardiac decompensation; blood pressure and pulse measurement. If required: contact with patients' physician.</description>
    <arm_group_label>regular, pharmacy-based intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 60 years and older

          -  Chronic heart failure (CHF)

          -  Stable CHF medication including a diuretic

          -  Hospitalization for decompensated heart failure within past 12 months OR a value of ≥
             350 pg/mL for BNP or ≥ 1,400 pg/mL for NT-proBNP

          -  Written informed consent

        Exclusion Criteria:

          -  Use of a weekly dosing aid

          -  Unwillingness or inability to visit a participating pharmacy once a week

          -  Planned cardiac surgery

          -  Life-expectancy &lt; 6 months

          -  Unwillingness or inability to comply with the study protocol (including drug abuse or
             alcohol dependency)

          -  Participation in other studies (currently or in the last 3 months)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Schulz, Prof. PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Federal Union of German Associations of Pharmacists</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrich Laufs, Prof. MD</last_name>
    <role>Study Chair</role>
    <affiliation>Saarland University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin Schulz, Prof. PhD</last_name>
    <phone>+49 (0) 30 40004</phone>
    <phone_ext>511</phone_ext>
    <email>arzneimittel@abda.aponet.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ulrich Laufs, Prof. MD</last_name>
    <phone>+49 (0) 6841 162</phone>
    <phone_ext>3412</phone_ext>
    <email>pharm.chf@uks.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Saarland University</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Laufs, Prof. MD</last_name>
      <phone>+49 (0)6841-162</phone>
      <phone_ext>3412</phone_ext>
      <email>pharm.chf@uks.eu</email>
    </contact>
    <investigator>
      <last_name>Ulrich Laufs, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.pharm-chf.de</url>
    <description>PHARM-CHF study home page</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 22, 2014</lastchanged_date>
  <firstreceived_date>September 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic heart failure</keyword>
  <keyword>medication adherence</keyword>
  <keyword>pharmacy</keyword>
  <keyword>interdisciplinary care</keyword>
  <keyword>randomized controlled trial</keyword>
  <keyword>mortality</keyword>
  <keyword>hospitalization</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
